Amir Tooreseenin brings over 15 years of experience in business development within the life sciences industry. He joined Atavistik Bio in 2023 as Vice President, Business Development. Prior to joining Atavistik, Amir was Vice President, Head of Corporate Development at Boston Pharmaceuticals where he was a member of the leadership team and was responsible for corporate strategy, in-licensing and out-licensing of assets, and other strategic transactions including capital raising. Previously, Amir was a member of the business development team at Alnylam Pharmaceuticals where he successfully led the execution of a number of strategic transactions, including the $2 billion strategic financing collaboration with Blackstone. Earlier in his career, Amir was a senior investment professional at Malin plc, a publicly listed investment corporation that led venture rounds in Immunocore, Kymab, and Xenex Disinfection Services, and Vice President in Evercore’s healthcare team where he helped execute on over $50 billion of announced M&A transactions.
Amir holds a BS in Mechanical Engineering from Purdue University and an MBA from Harvard Business School.